  |
Items where Author is "Mathuber, Marlene"
Group by: Item Type | No Grouping Jump to: Article Number of items: 4. ArticleDömötör, Orsolya and Mathuber, Marlene and Kowol, Christian R. (2024) In vitro biodistribution studies on clinically approved FGFR inhibitors ponatinib, nintedanib, erlotinib and the investigational inhibitor KP2692. EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES, 192. ISSN 0928-0987 Pósa, Vivien and Stefanelli, Alessia and Bormio Nunes, Julia H. and Hager, Sonja and Mathuber, Marlene and May, Nóra Veronika and Enyedy, Éva Anna (2022) Thiosemicarbazone Derivatives Developed to Overcome COTI-2 Resistance. CANCERS, 14 (18). No. 4455. ISSN 2072-6694 Bormio Nunes, Julia H. and Hager, Sonja and Mathuber, Marlene and Pósa, Vivien and Roller, Alexander and Enyedy, Éva A. (2020) Cancer Cell Resistance Against the Clinically Investigated Thiosemicarbazone COTI-2 is based on Formation of Intracellular Copper Complex Glutathione Adducts and ABCC1-Mediated Efflux. JOURNAL OF MEDICINAL CHEMISTRY, 63. pp. 13719-13732. ISSN 0022-2623 (print); 1520-4804 (online) Mathuber, Marlene and Schueffl, Hemma and Dömötör, Orsolya and Karnthaler, Claudia and Enyedy, Éva A. (2020) Improving the Stability of EGFR Inhibitor Cobalt(III) Prodrugs. Inorganic Chemistry, 59. pp. 17794-17810. ISSN 0020-1669 (print); 1520-510X (online) |
